Travere (NASDAQ: TVTX) CLO Reed exercises options and sells 10,000 shares

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Travere Therapeutics, Inc. executive Elizabeth E. Reed, the Chief Legal Officer and General Counsel, reported option exercises and share sales in Travere stock. On February 17, 2026, she exercised an employee stock option for 10,000 shares, acquiring the same number of Travere common shares at a reported exercise price of $19.08 per share. The option, granted on January 4, 2017 and expiring on January 4, 2027, is fully vested and exercisable. On the same date, she sold 5,679 shares at a weighted average price of $27.504 and 4,321 shares at a weighted average price of $28.262, in each case under a prearranged Rule 10b5-1 trading plan adopted on June 16, 2025. Following these transactions, she directly owns 105,211 shares of Travere common stock.

Insider Trade Summary

Net Seller: 10,000 shares ($278,315)

Net Sell 4 txns

Insider REED ELIZABETH E

Role Chief Legal Officer and GC

Sold 10,000 shs ($278K)

Type	Security	Shares	Price	Value
Exercise	Employee stock option (right to buy)	10,000	$0.00	--
Exercise	Common Stock	10,000	$19.08	$191K
Sale	Common Stock	5,679	$27.504	$156K
Sale	Common Stock	4,321	$28.262	$122K

Holdings After Transaction: Employee stock option (right to buy) — 20,000 shares (Direct); Common Stock — 115,211 shares (Direct)

Footnotes (1)

This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on January 4, 2017 with an expiration date of January 4, 2027. The weighted average sale price for the transaction reported was $27.504, and the range of prices were between $27.01 and $27.83. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. The weighted average sale price for the transaction reported was $28.262, and the range of prices were between $28.09 and $28.50. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. The stock option is fully vested and exercisable.

Form 4 Insider Transactions: What Each Field Means →

02/19/2026 - 04:10 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

REED ELIZABETH E

(Last)

(First)

(Middle)

C/O TRAVERE THERAPEUTICS, INC.

3611 VALLEY CENTRE DR., SUITE 300

(Street)

SAN DIEGO

92130

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Travere Therapeutics, Inc. [ TVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Legal Officer and GC

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/17/2026		M		10,000	A	$19.08	115,211	D
Common Stock	02/17/2026		S⁽¹⁾		5,679	D	$27.504⁽²⁾	109,532	D
Common Stock	02/17/2026		S⁽¹⁾		4,321	D	$28.262⁽³⁾	105,211	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Employee stock option (right to buy)	$19.08	02/17/2026		M			10,000	⁽⁴⁾	01/04/2027	Common Stock	10,000	$0	20,000	D

Explanation of Responses:

1. This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on January 4, 2017 with an expiration date of January 4, 2027.

2. The weighted average sale price for the transaction reported was $27.504, and the range of prices were between $27.01 and $27.83. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

3. The weighted average sale price for the transaction reported was $28.262, and the range of prices were between $28.09 and $28.50. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

4. The stock option is fully vested and exercisable.

	/s/ Elizabeth E. Reed	02/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Travere Therapeutics (TVTX) report for Elizabeth E. Reed?

Travere Therapeutics reported that Chief Legal Officer Elizabeth E. Reed exercised options for 10,000 shares and sold 10,000 common shares on February 17, 2026. These trades were executed under a prearranged Rule 10b5-1 plan and left her with 105,211 shares owned directly.

How many Travere Therapeutics (TVTX) shares did Elizabeth E. Reed sell and at what prices?

Elizabeth E. Reed sold a total of 10,000 Travere common shares, including 5,679 shares at a weighted average price of $27.504 and 4,321 shares at a weighted average price of $28.262. These sales occurred on February 17, 2026 under a Rule 10b5-1 plan.

Did Elizabeth E. Reed exercise stock options in Travere Therapeutics (TVTX)?

Yes. She exercised an employee stock option for 10,000 shares of Travere common stock on February 17, 2026. The option was granted January 4, 2017, is fully vested and exercisable, and carries an expiration date of January 4, 2027.

What is Rule 10b5-1 and how does it relate to the Travere (TVTX) insider sale?

The filing states that Elizabeth E. Reed’s share sales were made under a written Rule 10b5-1 trading plan adopted June 16, 2025. Such plans allow insiders to pre-schedule trades, helping separate personal trading activity from day-to-day informational access.

How many Travere Therapeutics (TVTX) shares does Elizabeth E. Reed own after these transactions?

After exercising options and selling shares, Elizabeth E. Reed directly owns 105,211 shares of Travere Therapeutics common stock. This figure reflects her updated direct ownership position as of the reported transactions on February 17, 2026.

What were the option grant details for the Travere (TVTX) shares exercised by Elizabeth E. Reed?

The stock option Reed exercised on February 17, 2026 covers 10,000 shares, was granted on January 4, 2017, and expires on January 4, 2027. The filing notes that the option is fully vested and exercisable at the time of the transaction.